Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03081052 · ClinicalTrials.gov registry record · Phase 4
Inhaled Selective Pulmonary Vasodilators for Advanced Heart Failure Therapies and Lung Transplantation Outcomes
A Phase 4 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 4
- Development phase
- 519
- Enrollment target
NCT03081052 is a Phase 4 study that has completed, run by Duke University. The registered enrollment target is 519 participants.
The verdict
NCT03081052, a Phase 4 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 519 participants
- Enrollment target
Study Summary
1\. to conduct a clinical investigation to determine if inhaled epoprostenol (Veletri®, iEPO) and inhaled nitric oxide (iNO) will have similar impact on outcomes in adult patients undergoing durable LVAD placement, heart transplantation, or lung transplantation 2. to conduct a cost-capture analysis on the expense each drug incurs per patient.
Interventions
- DRUG iNO
- DRUG iEPO
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 519 participants |
| Start Date | 2017-05-04 |
| Est. Completion | 2021-09-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03081052
The ClinicalTrials.gov registry entry for NCT03081052 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 519 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which iNO is the first listed.
NCT03081052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03081052 about?
NCT03081052 is a clinical study titled "Inhaled Selective Pulmonary Vasodilators for Advanced Heart Failure Therapies and Lung Transplantation Outcomes". 1\. to conduct a clinical investigation to determine if inhaled epoprostenol (Veletri®, iEPO) and inhaled nitric oxide (iNO) will have similar impact on outcomes in adult patients undergoing durable LVAD placement, heart transplantation, or lung transplantation 2. to conduct a cost-capture analysis ...
What is the current status of trial NCT03081052?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 519 participants. The study started on 2017-05-04. Estimated completion is 2021-09-05.
What interventions are being tested in trial NCT03081052?
The interventions under investigation include: iNO (DRUG), iEPO (DRUG).
Who is sponsoring clinical trial NCT03081052?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.